Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor.

Li WQ, Yu HY, Li YM, Wang X, He J, Yan HZ, Yang DH, Wu XJ, Hou LJ, Liu HM, Xia CY, Lu YC.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):1261-7. doi: 10.1016/j.bbrc.2014.03.105. Epub 2014 Mar 29.

PMID:
24690174
2.

MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme.

Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu H, Chen J, He J, Yu H.

Brain Res. 2009 Aug 25;1286:13-8. doi: 10.1016/j.brainres.2009.06.053. Epub 2009 Jun 24.

PMID:
19559015
3.

MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1.

Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su JL, Zhang MH, Liang HQ.

J Biol Chem. 2015 Apr 3;290(14):8938-48. doi: 10.1074/jbc.M114.624700. Epub 2015 Feb 10.

4.

MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.

Costa PM, Cardoso AL, Nóbrega C, Pereira de Almeida LF, Bruce JN, Canoll P, Pedroso de Lima MC.

Hum Mol Genet. 2013 Mar 1;22(5):904-18. doi: 10.1093/hmg/dds496. Epub 2012 Nov 30.

5.

MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme.

Li WB, Ma MW, Dong LJ, Wang F, Chen LX, Li XR.

Cancer Biol Ther. 2011 Sep 15;12(6):477-83. doi: 10.4161/cbt.12.6.16300. Epub 2011 Sep 15.

PMID:
21743299
6.

Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway.

Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR, Mischel PS, Viapiano M, Kornblum HI.

Neuro Oncol. 2011 Jun;13(6):622-34. doi: 10.1093/neuonc/nor023. Epub 2011 May 9.

7.

Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Gaur AB, Holbeck SL, Colburn NH, Israel MA.

Neuro Oncol. 2011 Jun;13(6):580-90. doi: 10.1093/neuonc/nor033.

8.

Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme.

Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y, Jiang T.

Brain Res. 2011 Sep 9;1411:108-15. doi: 10.1016/j.brainres.2011.07.002. Epub 2011 Jul 13.

PMID:
21831363
9.

MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6.

Chen SM, Chen HC, Chen SJ, Huang CY, Chen PY, Wu TW, Feng LY, Tsai HC, Lui TN, Hsueh C, Wei KC.

World J Surg Oncol. 2013 Apr 17;11:87. doi: 10.1186/1477-7819-11-87.

10.

The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas.

Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y, Zhou LF.

Brain Res. 2013 Sep 5;1529:16-25. doi: 10.1016/j.brainres.2013.07.031. Epub 2013 Jul 26.

PMID:
23892108
11.

MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated.

Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y, Mao Q.

Exp Cell Res. 2014 Jan 15;320(2):200-8. doi: 10.1016/j.yexcr.2013.10.020. Epub 2013 Nov 5.

PMID:
24211747
12.

Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes.

Zhang S, Han L, Wei J, Shi Z, Pu P, Zhang J, Yuan X, Kang C.

Int J Oncol. 2015 Apr;46(4):1589-600. doi: 10.3892/ijo.2015.2841. Epub 2015 Jan 22.

PMID:
25625875
13.

Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.

Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U.

Oncology. 2009;76(3):184-9. doi: 10.1159/000201943. Epub 2009 Feb 13.

PMID:
19218824
15.

Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.

Liu S, Yin F, Fan W, Wang S, Guo XR, Zhang JN, Tian ZM, Fan M.

J Exp Clin Cancer Res. 2012 May 31;31:52. doi: 10.1186/1756-9966-31-52.

16.

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.

Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN.

Clin Cancer Res. 2008 Jun 15;14(12):3993-4001. doi: 10.1158/1078-0432.CCR-07-4152.

17.

PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.

Liu Y, Carlsson R, Ambjørn M, Hasan M, Badn W, Darabi A, Siesjö P, Issazadeh-Navikas S.

J Neurosci. 2013 Aug 28;33(35):14231-45. doi: 10.1523/JNEUROSCI.5812-12.2013.

18.

Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.

Ning S, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):197-203.

PMID:
15337556
19.
20.

Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).

Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kölbl O, Flentje M.

BMC Cancer. 2006 Oct 18;6:247.

Supplemental Content

Support Center